Protocol Ledger

NCT07546812 · Phase II · RECRUITING

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Interventional Phase II clinical trial protocol NCT07546812 sponsored by Gilead Sciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-07 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07546812
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07546812
Protocol FieldVerified Registry Value
NCT IdentifierNCT07546812
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2026-08-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07546812
Hospital Research SiteLocationSite Profile
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Weill Cornell MedicineNew York, NYOpen Hospital Dossier ->
Chris O'Brien LifehouseCamperdown, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI